AAV9 Potency Assay Using Differentiated Neural Progenitor Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for a robust and quantitative in vitro cell-based assay to determine the relative potency of AAV9 drug products, as existing cell lines are not permissive to AAV9 vector transduction, hindering the development of a reliable method for measuring transgene expression.

Innovation Solution

The use of terminally differentiated, non-dividing cells derived from neural progenitor cells under the SMN1 −/− genetic background (mTD-NPC-Δ7) that are capable of being effectively transduced by non-replicating AAV9 vectors, combined with a high-content imaging system and monoclonal antibodies, to measure dose-dependent protein expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If existing cell lines (e.g., HeLa RC32) are used for AAV9 transduction assays, then the assay system is readily available, but the cells are not permissive to AAV9 vector transduction, resulting in inability to measure transgene expression

Engineering Contradiction:

Improveavailability of cell lineVSAvoidtransduction permissiveness

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the cellular state parameter from proliferating to terminally differentiated, which enables permissiveness to AAV9 transduction. Specifically, the invention uses terminally differentiated neural progenitor cells (mTD-NPC-Δ7) that have lost the ability to divide but gain the ability to accept AAV9 vectors and express transgenes, thereby resolving the contradiction between cell availability and transduction efficiency

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent inverts the typical assumption that proliferating cells are the standard for viral vector assays. Instead of using conventional dividing cell lines, the invention employs terminally differentiated cells that are non-permissive to replication but permissive to transduction, achieving the opposite state to enable reliable AAV9 potency measurement

Inventive Principle:

Principle #13The other way round (Inversion)

2Reliability

If terminally differentiated neural progenitor cells are used, then AAV9 transduction permissiveness is achieved, but the cells are non-dividing and require specific culture conditions

Engineering Contradiction:

Improvetransduction permissivenessVSAvoidculture system requirements

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses an intermediary cell model system (mTD-NPC-Δ7 cells) that bridges the gap between AAV9 vector delivery and transgene expression measurement. These cells serve as a specialized intermediary that is both permissive to AAV9 and amenable to quantitative protein expression analysis, resolving the complexity by providing a dedicated assay system

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If a robust quantitative assay is developed, then measurement precision of viral potency is improved, but the assay complexity and development time increase

Engineering Contradiction:

Improveviral infectious titer measurementVSAvoidassay system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical cell culture systems with a simplified high-content imaging-based assay. By using terminally differentiated cells that naturally express the transgene and combining this with automated image analysis, the invention achieves precise quantitative measurement without requiring complex multi-step protocols, thereby improving measurement precision while controlling assay complexity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables a quantitative assessment of AAV9 vector potency through a robust in vitro assay, allowing for accurate measurement of transgene expression and viral infectious titer, thereby ensuring the quality and consistency of AAV9-based gene therapy products.

Implementation Method 1

The cells are permissive to transduction by non-replicating AAV9 vectors

Methodology Applied

Scientific EffectViral transduction:

Implementation Method 2

contacting the plurality of cells with a molecule specific for the protein of interest

Methodology Applied

Scientific EffectAntibody-protein binding:

Implementation Method 3

imaging the cell to obtain an integrated fluorescent intensity per cell (IFI-C) assay readout

Methodology Applied

Scientific EffectFluorescence detection: Fluorescence

Data Source

PatentUS20250369967A1Cell-based assay for measuring drug product potency

Publication Date: 2025.12.04 NOVARTIS AG

AI summary

The invention relates to the an in vitro quantitative cell-based assay that uses a primary mouse cell model system permissive to viral vector infection and a quantitative high content imaged-based system for determining potency of a transgene-expressing viral vector drug product for lot disposition.